Analyst: Positive results from Ambu's Duodeno 1.5 reflected in Ambu shares
On Monday, Ambu reported that 59 of 60 procedures completed with its improved duodenoscope, the Ascope Duodeno 1.5, were successful in a recent clinical test. An analyst from Sydbank sees the rewards in Ambu's share price.
by marketwire, translated by daniel pedersen
Today's positive results from Ambu's clinical study with its new and improved duodenoscope product, the Ascope Duodeno 1.5, have been received well by investors, who have sent Ambu's share price up, as observed by Senior Equity Analyst at Sydbank Søren Løntoft Hansen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
